FDA Guidance Provides Relief for MDR Reporting During a Pandemic
Exeed Regulatory Compliance
MARCH 22, 2020
A new FDA guidance provides much-needed relief during a pandemic. FDA has just revised its relatively less known 2012 guidance entitled “Post-market Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic” to clarify that the guidance is applicable to any pandemic, not just an influenza pandemic.
52 
Let's personalize your content